A study found that undergoing a cardiac ablation procedure first—before taking any antiarrhythmic therapies—may be the better ...

A preliminary study of an artificial intelligence-powered program found that it could detect if a person had high blood ...

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for ...

A spin-out from the University of Edinburgh in Scotland is already equipped with 15 million pounds ($19 million) in seed ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Philips has secured an FDA clearance for what it describes as the world’s first imager to combine spectral CT with ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...